Paper Details

  1. Home
  2. Paper Details

A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.

Author: HalperinScott A, LangleyJoanne M, MacDonaldLisa D, MacKinnon-CameronDonna, McNeilShelly, SaelensXavier, SchepensBert, StanfordMarianne M, WeirGenevieve M, YeLingyun

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A novel synthetic respiratory syncytial virus (RSV) antigen based on the ectodomain of the small hydrophobic glycoprotein (SHe) of RSV subgroup A, formulated with the lipid and oil-based vaccine platform DepoVax (DPX-RSV[A]), was highly immunogenic, with sustained antigen-specific antibody responses, and had an acceptable safety profile.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Respiratory syncytial virus infection can cause lower respiratory tract infection in older adults comparable to influenza, but no vaccines are available. METHODS: This was a randomized, observer-blinded, first-in-humans study of a novel synthetic RSV antigen based on the ectodomain of t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049039/

データ提供：米国国立医学図書館（NLM）

A New Hope for RSV: A Novel Vaccine Shows Promise

Respiratory syncytial virus (RSV) is a common respiratory virus that can cause serious illness, particularly in infants, young children, and older adults. Currently, there are no vaccines available for RSV, but this study provides a glimmer of hope with the development of a novel vaccine candidate. The researchers conducted a first-in-humans trial of a vaccine based on the small hydrophobic glycoprotein (SHe) of RSV, formulated with a lipid and oil-based delivery platform. The vaccine showed promising results in terms of immunogenicity and safety in healthy adults.

A Promising Step Toward RSV Prevention

The study demonstrated that the novel vaccine candidate, formulated with the DepoVax platform, elicited robust and sustained antibody responses against SHe in healthy adults. This is a significant step towards the development of a safe and effective RSV vaccine. The vaccine was well-tolerated, with only mild side effects. These findings are encouraging and suggest that this vaccine could potentially offer protection against RSV in vulnerable populations.

The Quest for an RSV Vaccine: A Long and Winding Road

This research highlights the ongoing efforts to develop a safe and effective vaccine against RSV. While the results of this early-stage trial are promising, further research is needed to confirm the vaccine's long-term efficacy and safety in different populations. The development of an RSV vaccine would be a major breakthrough in public health, offering protection against this debilitating virus. As a researcher, I am excited about the potential of this vaccine candidate to transform the landscape of RSV prevention.

Dr.Camel's Conclusion

This study presents a promising new vaccine candidate for RSV, offering hope for future prevention strategies. Just like a camel traversing a vast desert, we must continue to explore new avenues in the quest for a solution to this prevalent health concern.

Date :
  1. Date Completed 2019-09-12
  2. Date Revised 2019-09-12
Further Info :

Pubmed ID

29617814

DOI: Digital Object Identifier

PMC6049039

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.